Vela Diagnostics Announces Pre-Launch of an Automated Next-Generation Sequencing (NGS) Solution

Singapore (May 28, 2014) – Vela Diagnostics announced today the pre-launch of its automated Next-Generation Sequencing (NGS) solution that is expected to launch in third quarter of 2014 as a CE-IVD device in Europe and followed by Australia in the fourth quarter of 2014.

Vela Diagnostics’ NGS solution is highly automated and shares components with its existing qPCR workflow, providing the first solution combining PCR and NGS in an automated workflow.

“Our Sentosa® SX101 platform has the unique ability to seamlessly integrate both qPCR and NGS solutions from our menu of assays. The modularity approach will reinforce our position in the market by enabling laboratories to meet their workflow needs and their expansion plans.” said Vela Diagnostics CEO Michael Tillmann.

The Vela Diagnostics NGS solution addresses the specific requirements of the laboratory. The automated workflow offers sample tracking ability and LIS interface capabilities. The solution includes software for intuitive and powerful results analysis thus minimizing the need for bioinformatics expertise typically associated with sophisticated NGS data analysis, coupled with automated report generation.

In conjunction with the launch, Vela will be introducing an Early Access Program (EAP). Vela expects the NGS solution to begin shipping commercially in August 2014 to our EAP customers.

 

Vela is a trademark of Vela Holding Pte Ltd. Sentosa is a registered trademark of Vela Holding Pte Ltd in several markets including the US and the European Union.

Go back